SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DMTC or DIAMOND The Cat Coin is a viral meme coin on Solana Blockchain, Based in Thailand and Global and Based on a true story about my lovely cat(DIAMOND) and made by love, I just want my cat to be immortal in this whole world until I die that's a first idea of this project start. We're start from $2,000 Market cap and hit All time high at $10.9 million, please come to check our project and let's DMTC get list on Coingecko to let's everyone in this whole world know DMTC.

DIAMOND The Cat Coin

Diamond The Cat Coin ($DMTC.X) is gaining attention as traders discuss its potential for a significant breakout, fueled by strong buying activity and a build-up of energy on the charts. Community members highlight positive chart signals and increasing volume, suggesting a possible surge. The coin is being touted as a hidden gem with momentum, with many anticipating substantial gains.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis (AVNT.X) is trending as community members discuss its recent price surge and potential for further growth, with some drawing comparisons to other successful tokens. Attention is focused on its backers and potential for trading real-world assets, while others are speculating about near-term price targets. The community highlights that it is a top gainer on Coinbase.

Hecla Mining Co. engages in the provision of precious and base metals. It operates through the following segments: Greens Creek, Lucky Friday, Keno Hill, Casa Berardi, and Other. The company was founded by Amasa B. Campbell, Patsy Clark, and John Finch on October 14, 1891 and is headquartered in Coeur d'Alene, ID.

Hecla Mining Co.

Hecla Mining is trending as discussions revolve around the potential impact of rising silver and gold prices on the company. Community members are also actively discussing Hecla's inclusion in the S&P SmallCap 600 index, which may lead to increased passive investment flows. Broader positive sentiment in the materials sector is also seen as a potential tailwind for the stock.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as the top memecoin on Bitcoin, distinguished by its fair launch and strong community backing. With a focus on decentralization and a fixed supply, the community emphasizes its potential for significant growth within the Bitcoin ecosystem. Discussions highlight its unique position as a Bitcoin-native meme coin, contrasting it with Ethereum and Solana-based alternatives.

Pump.fun

$PUMP.X is trending as the community highlights its position as a key player in the Solana meme coin ecosystem, with many pointing to the project's continued buybacks. Community members are actively discussing potential price targets and expressing excitement about its potential for significant gains in the current cycle. Some are calling it the 'NASDAQ of shit coins' and believe it will lead the altcoin season.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is trending as the community discusses a recent multi-billion dollar contract and a potential equity stake from the Trump administration. Some are analyzing the implications of this news alongside mentions of AI and hypersonic technology. Despite a recent dip and lowered guidance, many view LMT as a long-term play due to geopolitical factors and its strong position in the defense sector.

Binance Coin is the cryptocurrency of the Binance platform. It is a trading platform exclusively for cryptocurrencies. The name "Binance" is a combination of binary and finance.  Thus, the startup name shows that only cryptocurrencies can be traded against each other. It is not possible to trade crypto currencies against Fiat. The platform achieved an enormous success within a very short time and is focused on worldwide market with Malta headquarters. The cryptocurrency currently has a daily trading volume of 1.5 billion - 2 billion US dollars and is still increasing.  In total, there will only be 200 million BNBs. Binance uses the ERC20 token standard from Ethereum and has distributed it as follow: 50% sold on ICO, 40% to the team and 10% to Angel investors. The coin can be used to pay fees on Binance. These include trading fees, transaction fees, listing fees and others. Binance gives you a huge discount when fees are paid in BNB.   The schedule of BNB fees discount is as follow: In the first year, 50% discount on all fees, second year 25% discount, third year 12.5% discount, fourth year 6.75 % discount, and from the fifth year onwards there is no discount. This structure is used to incentivize users to buy BNB and do trades within Binance.  Binance announced in a buyback plan that it would buy back up to 100 million BNB in Q1 2018. The coins are then burned. This means that they are devaluated to increase the value of the remaining coins. This benefits investors. In the future, the cryptocurrency will remain an asset on the trading platform and will be used as gas.  Other tokens that are issued by exchanges include Bibox Token, OKB, Huobi Token, and more.

Binance

Binance's BNB.X is currently trending as the crypto community discusses its impressive rally and potential targets, including speculation about reaching $1000 soon. The recent partnership between Binance and Franklin Templeton to develop digital asset initiatives has also generated significant buzz. Discussions also involve the potential for Solana to surpass BNB.X in market capitalization.

Volatility Shares Trust - 2x Solana ETF

Volatility Shares 2x Solana ETF

Volatility Shares 2x Solana ETF ($SOLT) is trending as traders discuss its leveraged exposure to Solana ($SOL.X) and potential for outsized gains. Community members are weighing the risks and rewards of this 2x ETF, with some anticipating significant upside if Solana continues its upward trajectory, while others point to the risks of leverage decay. Bullish sentiment around Solana's potential to outperform Ethereum and Bitcoin is also fueling interest in $SOLT.

MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. It focuses on the development and manufacturing of genetic medicines to treat both inherited and more common conditions with severe unmet need. The company was founded on March 20, 2015 and is headquartered in New York, NY.

MeiraGTx Holdings plc

MeiraGTx (MGTX) is trending following news of a strategic investment from Sanofi, with the community viewing this as a strong signal of confidence in the company's gene therapy platform and pipeline. Discussions revolve around potential implications for future partnerships, acquisitions, and the undervalued nature of MGTX relative to its assets. Optimism is fueled by upcoming catalysts and the potential for significant revenue growth.

BRETT the dancer, gamer, and cultural icon of BASE chain (some like to call me the PEPE of BASE).

Brett

BRETT.X is trending as the community anticipates a potential breakout and future Coinbase listing, while also weighing its potential against other Base chain memecoins like $TOSHI.X and new competitors. Discussions revolve around market cap predictions, entry points, and overall bullish sentiment for the long term. Some traders point to technical indicators suggesting a possible upswing, while others express concerns about ownership concentration.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Options Traders Betting on a Big Move in BCRX Stock?

Investors need to pay close attention to BioCryst Pharmaceuticals stock based on the movements in the options market lately.

BioCryst Pharmaceuticals, Inc. (BCRX) is now looking forward to data on its Netherton Syndrome and DME pipeline programs after its second-quarter earnings beat Wall Street expectations on the strong performance of its Orladeyo drug.“Our Netherton Syndrome and DME (diabetic macular edema) pipeline programs remain on track to have some data by the end of the year,” said CEO Jon Stonehouse on the company’s earnings call on Monday. The company is enrolling patients for an early-stage trial of both investigational drugs.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BCRX">BCRX</a> is trending in the ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_04_at_11_07_20_AM_png_98d2936188.webp" alt="BCRX's Sentiment Meter and Message Volume as of 11:05 a.m. ET on Aug. 4, 2025 | Source: Stocktwits" width="627" height="63"><figcaption>BCRX's Sentiment Meter and Message Volume as of 11:05 a.m. ET on Aug. 4, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock’s fair valuation is double its current level.<stembedurl>https://stocktwits.com/doublebtx/message/623619202</stembedurl>Another expressed disappointment at the stock’s slow rally.<stembedurl>https://stocktwits.com/coleslaugh/message/623622668</stembedurl>Netherton syndrome is a rare genetic disorder primarily affecting the skin, hair, and immune system, in which patients experience severe skin problems, including redness, scaling, and blistering, as well as hair abnormalities like bamboo hair.DME, meanwhile, is a leading cause of vision loss in people with diabetes. Fluid accumulates in the central part of the eye’s retina, causing swelling and blurry or distorted vision.A company spokesperson said on the call that the firm is looking at data on several endpoints, including the penetration of the drug in the skin, and on potential efficacy endpoints, including itching and healing of the skin with its investigational drug for Netherton syndrome. For the company’s investigational drug for DME, the company is looking at the effect of the drug on the retina and the potential for reducing the swelling in the retina after a dose of the drug.For the second quarter, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.biocryst.com/news-releases/news-release-details/biocryst-reports-second-quarter-2025-financial-results-and">reported</a> total revenue of $163.35 million, compared to $109.33 million in the corresponding quarter of 2024, and above an analyst estimate of $149.22&nbsp;&nbsp;&nbsp;&nbsp;million, as per data from Fiscal AI.Orladeyo, the company’s medicine used to prevent attacks of hereditary angioedema (HAE), accounted for a whopping 96% of the company’s total revenue in the quarter. Orladeyo's net revenue in the quarter jumped 45% to $156.8 million.For the full year, the company now expects global net Orladeyo revenue to be between $580 million and $600 million, even when excluding fourth quarter European revenue after the expected closing of the sale of its European business. Biocryst in June said that it has entered into a definitive agreement to sell its European Orladeyo business to Neopharmed Gentili for up to $264 million. Closing of the transaction is expected by early October.The company said that it also remains on track to deliver net income and positive cash flows for the full year 2025.BCRX stock is up by about 12% this year and over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/joby-aviation-announces-purchase-of-blade-urban-air-mobility-business/chrXN6wRdTY">Joby Aviation Stock Flies 15% After Company Announces Purchase Of Blade’s Urban Air Mobility Business: Retail’s Not Entirely Convinced</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level

CEO Jon Stonehouse stated during the company’s earnings call on Monday that the firm’s Netherton Syndrome and DME pipeline programs remain on track to have some data by the end of the year. 

Equity

BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of +400.00% and +9.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock

BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?

Here is how BioCryst Pharmaceuticals (BCRX) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Ensign Group Boosts U.S. Presence With Idaho and Texas Facility Buyouts 

ENSG adds Idaho and Texas facilities to its skilled nursing facility and real estate portfolios and earns an opportunity to boost revenues by catering to growing patient volumes. 

Select Medical Expands Presence in Tennessee With Ballad Health Deal

SEM partners with Ballad Health to relocate and expand its Tri-Cities critical illness recovery hospital, boosting care access in Tennessee by being able to treat more patients grappling with serious illnesses. 

BioCryst Pharmaceuticals, Inc. (BCRX) on Friday said that it has entered into a definitive agreement to sell its European Orladeyo business to Italian pharmaceutical company Neopharmed Gentili for up to $264 million.BCRX shares were up by over 4% in the pre-market session, following the news.As per the terms of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.biocryst.com/news-releases/news-release-details/biocryst-announces-sale-european-orladeyor-berotralstat-business">agreement</a>, Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to Orladeyo. Biocryst is also eligible to receive up to $14 million in future milestone payments.Orladeyo, also known as berotralstat, is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in adults and children 12 years of age and older. Hereditary angioedema (HAE) is a rare genetic disorder causing recurring episodes of severe swelling in various body parts, including the limbs, face, intestinal tract, and airway.<a href="https://stocktwits.com/symbol/BCRX">BioCryst</a> plans to use the proceeds from the transaction to retire all remaining term debt of $249 million from Pharmakon, which will eliminate approximately $70 million of future interest payments.The biotech company expects the transaction to result in at least $50 million in expected annual operating expense savings for BioCryst. It also expects to end 2027 with approximately $700 million in cash and no term debt, marking an increase of $400 million from its previous 2027 net cash guidance.In the first quarter (Q1) of 2025, BioCryst reported Orladeyo net revenue of $134.2 million, marking a growth of 51% year-on-year. Oraledyo revenue, in fact, accounted for about 92% of the company’s overall revenue in the period.However, sales from the U.S. contributed 89.5% of global Orladeyo net revenues in the first quarter, implying the European business accounted for only a small portion.On Stocktwits, retail sentiment around BCRX stayed unchanged within ‘bearish’ territory over the past 24 hours, accompanied by ‘low’ levels of retail chatter.<figure class="image"><img style="aspect-ratio:1250/134;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_27_at_7_45_04_AM_png_68794667d1.webp" alt="BCRX's Sentiment Meter and Message Volume as of 7:45 a.m. ET on June 27, 2025 | Source: Stocktwits" width="1250" height="134"><figcaption>BCRX's Sentiment Meter and Message Volume as of 7:45 a.m. ET on June 27, 2025 | Source: Stocktwits</figcaption></figure>However, a Stocktwits user expressed surprise at the deal and opined that the additional cash makes it easier for the company to find a buyer if that is what it intends to do.<stembedurl>https://stocktwits.com/justfkntrade/message/619211689</stembedurl>Another opined that the deal makes the company an ‘irresistible candy’ with no debt.<stembedurl>https://stocktwits.com/gdesivir/message/619209736</stembedurl>Biocryst had also said in May that it expects to be profitable for the full year 2025, a year ahead of schedule.BCRX stock is up by 28% this year and by about 58% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-slams-eu-as-closed-for-business-after-200-m-fine-warning-of-daily-penalties/chmguP6RRIt">Meta Slams EU As ‘Closed For Business’ After $200M Fine, Warning of Daily Penalties</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

BioCryst To Sell European Business Of Its Hereditary Angioedema Drug To Pay Off Debt: Stock Rises While Retail Stays Bearish

As per the terms of the agreement, Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to Orladeyo and the company will also be eligible to receive up to $14 million in future milestone payments.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

BCRX
Biocryst Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BCRX News

BCRX Biocryst Pharmaceuticals Inc.